X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (490) 490
oncology (302) 302
immunotherapy (301) 301
humans (242) 242
nivolumab (232) 232
immunology (231) 231
immune-related adverse events (219) 219
animals (204) 204
ipilimumab (181) 181
melanoma (173) 173
immune-related genes (172) 172
cancer (168) 168
pembrolizumab (141) 141
fisheries (140) 140
analysis (138) 138
gene expression (124) 124
marine & freshwater biology (119) 119
male (117) 117
female (114) 114
care and treatment (107) 107
immune-related response (106) 106
patients (103) 103
metastasis (101) 101
genes (99) 99
veterinary sciences (99) 99
metastatic melanoma (98) 98
immune-related adverse event (90) 90
immune checkpoint inhibitors (88) 88
immune response (87) 87
chemotherapy (85) 85
adverse events (82) 82
aged (82) 82
expression (81) 81
middle aged (81) 81
research (79) 79
therapy (79) 79
case report (76) 76
docetaxel (72) 72
complications and side effects (70) 70
lung cancer (69) 69
advanced melanoma (68) 68
antibodies, monoclonal - adverse effects (64) 64
health aspects (64) 64
immune system (64) 64
open-label (64) 64
cancer therapies (63) 63
antibodies, monoclonal - therapeutic use (57) 57
adult (56) 56
genetic research (56) 56
pd-1 (56) 56
neoplasms. tumors. oncology. including cancer and carcinogens (55) 55
immune checkpoint inhibitor (54) 54
blockade (53) 53
checkpoint inhibitors (52) 52
cell lung-cancer (51) 51
solid tumors (51) 51
treatment outcome (51) 51
safety (50) 50
survival (50) 50
tumors (50) 50
fish (49) 49
immune checkpoint (48) 48
innate immunity (48) 48
antibodies (47) 47
pharmacology & pharmacy (47) 47
melanoma - drug therapy (46) 46
rainbow-trout (46) 46
usage (46) 46
medicine & public health (45) 45
proteins (45) 45
toxicity (45) 45
apoptosis (44) 44
immunotherapy - methods (44) 44
lymphocytes (44) 44
drug therapy (41) 41
management (41) 41
programmed cell death 1 receptor - antagonists & inhibitors (41) 41
anti-pd-1 (40) 40
antigens (40) 40
development and progression (40) 40
fish diseases - immunology (40) 40
review (40) 40
antineoplastic agents - therapeutic use (39) 39
article (39) 39
criteria (39) 39
antineoplastic agents - adverse effects (38) 38
clinical trials (38) 38
lung cancer, non-small cell (38) 38
rna (38) 38
autoimmunity (37) 37
genetic aspects (37) 37
lung neoplasms - drug therapy (37) 37
medical research (37) 37
aged, 80 and over (36) 36
immunotherapy - adverse effects (36) 36
t cells (36) 36
disease resistance (35) 35
respiratory system (35) 35
biochemistry & molecular biology (34) 34
cytokines (34) 34
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (920) 920
Japanese (10) 10
French (4) 4
Chinese (1) 1
German (1) 1
Korean (1) 1
Portuguese (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 01/2019, Volume 46, Issue 1, pp. 238 - 250
This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of... 
Immune checkpoint inhibitors | Therapy response | Immune-related side effects | Hyperprogression | Pseudoprogression | Immunotherapy | CRITERIA | F-18-FDG PET/CT | METASTATIC MELANOMA PATIENTS | INFILTRATING LYMPHOCYTES | HETEROGENEITY | LUNG-CANCER | THERAPY | METABOLIC-ACTIVITY | NIVOLUMAB | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | IPILIMUMAB
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 19, pp. 5737 - 5744
Purpose: We evaluated tumor burden dynamics in patients with advanced non-small cell lung cancer (NSCLC) treated with commercial PD-1 inhibitors to identify... 
PSEUDOPROGRESSION | THERAPY | PEMBROLIZUMAB | ONCOLOGY | GUIDELINES | IMMUNE-RELATED RESPONSE | EGFR MUTATIONS | EVALUATION CRITERIA | NIVOLUMAB | NSCLC PATIENTS | PROGRESSION | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Protein Kinase Inhibitors - immunology | Aged, 80 and over | Adult | Female | Tumor Burden - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Erlotinib Hydrochloride - adverse effects | Carcinoma, Non-Small-Cell Lung - genetics | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - genetics | Therapy | PD-1 protein | Lung cancer | Medical services | Markers | Non-small cell lung carcinoma | Hazards | Disease control | Patients | Dynamic tests | Inhibitors | Experimental design | Smoking | Cancer | pseudoprogression | PD-1 inhibitor | tumor response | immunotherapy | non-small-cell lung cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2018, Volume 101, pp. 229 - 235
BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) are among the cornerstones of metastatic melanoma therapy demonstrating excellent response rates with... 
Metastatic melanoma | BRAF inhibitor melanoma | Immune-related adverse events | Targeted Therapy | SURVIVAL | MULTICENTER | MONOTHERAPY | OPEN-LABEL | PHASE-3 | DABRAFENIB PLUS TRAMETINIB | PEMBROLIZUMAB | ONCOLOGY | CUTANEOUS MELANOMA | ASSOCIATION | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Arthralgia - chemically induced | Young Adult | Pyridones - administration & dosage | Vemurafenib - administration & dosage | Neoplasm Metastasis | Melanoma - genetics | Aged, 80 and over | Adult | Female | Retrospective Studies | Vemurafenib - adverse effects | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Azetidines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Skin Neoplasms - genetics | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Complications and side effects | Care and treatment | Immune response | Analysis | Immunotherapy | Melanoma | Metastasis
Journal Article
Journal Article
Journal Article
AMERICAN JOURNAL OF ROENTGENOLOGY, ISSN 0361-803X, 06/2019, Volume 212, Issue 6, pp. 1177 - 1181
OBJECTIVE. The purpose of this study is to assess the frequency of atypical response patterns in oncology patients treated with the programmed cell death... 
pseudoprogression | CRITERIA | nivolumab | immunotherapy | GUIDELINES | IMMUNE-RELATED RESPONSE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | atypical response
Journal Article
Fish and Shellfish Immunology, ISSN 1050-4648, 04/2014, Volume 37, Issue 2, pp. 209 - 214
Journal Article